Group 1 - The company plans to jointly invest 97 million yuan to establish a subsidiary named Haishi Biotechnology Co., Ltd., with an investment of 87 million yuan from the company, holding 89.69% equity [1] - Haishi Biotechnology will focus on cutting-edge areas such as ADC (Antibody-Drug Conjugates) and In Vivo CART (Chimeric Antigen Receptor T-cell Therapy) [1] - The company also intends to jointly invest 48.5 million yuan to establish another subsidiary named Haishi Xinyuan Pharmaceutical Technology Co., Ltd., with an investment of 43.5 million yuan from the company, also holding 89.69% equity [1] - Haishi Xinyuan will concentrate on research in new-generation technologies such as small nucleic acid drugs [1] Group 2 - Hailekes is fully owned by the company's controlling shareholder, Wang Junmin [2]

Core Viewpoint - The company, Heisico (002653.SZ), plans to jointly invest with Helix (Chengdu) Pharmaceutical Technology Co., Ltd. to establish two subsidiaries focusing on advanced biopharmaceutical technologies [1] Group 1: Investment Details - The total investment for the establishment of the subsidiary Heisibiotechnology Co., Ltd. is 97 million RMB, with Heisico investing 87 million RMB for an 89.69% equity stake, while Helix invests 10 million RMB for a 10.31% stake [1] - The focus of Heisibiotechnology will be on cutting-edge areas such as ADC (Antibody-Drug Conjugates) and In Vivo CART (Chimeric Antigen Receptor T-cell Immunotherapy) [1] Group 2: Second Subsidiary Investment - The total investment for the establishment of the subsidiary Heisixinyuan Pharmaceutical Technology Co., Ltd. is 48.5 million RMB, with Heisico investing 43.5 million RMB for an 89.69% equity stake, while Helix invests 5 million RMB for a 10.31% stake [1] - Heisixinyuan will focus on research in new-generation technologies such as small nucleic acid drugs [1]